HLA and autoimmune digestive disease: A clinically oriented review for gastroenterologists

American Journal of Gastroenterology

Volumn 104, Issue 1, 2009, Pages 195-217

  Cassinotti, Andrea ^a   Birindelli, Sarah ^a   Clerici, Mario ^b   Trabattoni, Daria ^b   Lazzaroni, Marco ^a   Ardizzone, Sandro ^a   Colombo, Riccardo ^a   Rossi, Edoardo ^a   Porro, Gabriele Bianchi ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B ANTIGEN; HLA B51 ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA ANTIGEN;

ALLELE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN SPECIFICITY; ANTIGEN STRUCTURE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE PANCREATITIS; BEHCET DISEASE; CELIAC DISEASE; CLINICAL PRACTICE; DATA BASE; DISEASE ASSOCIATION; ENTERITIS; GASTROINTESTINAL DISEASE; GENE DOSAGE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RESISTANCE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HLA SYSTEM; HLA TYPING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPATHOGENESIS; LINKAGE ANALYSIS; MARKER GENE; MEDLINE; NOMENCLATURE; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCLEROSING CHOLANGITIS; SIGNAL DETECTION; BILIARY CIRRHOSIS; DIGESTIVE SYSTEM DISEASE; GENETICS; IMMUNOLOGY;

AUTOIMMUNE DISEASES; CELIAC DISEASE; CHOLANGITIS, SCLEROSING; DIGESTIVE SYSTEM DISEASES; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS, AUTOIMMUNE; HLA ANTIGENS; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER CIRRHOSIS, BILIARY;

EID: 60749125324     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.10     Document Type: Review

References (270)

1. Hugh H, Fudenberg JRL, Wang AC et al. Basic Immunogenetics, 3rd edn, Oxford University Press: London, 1984.
2. Ploegh HL, Orr HT, Strominger JL. Major histocompatibility antigens: the human (HLA-A, -B, -C) and murine (H-2K, H-2D) class I molecules. Cell 1981;24:287-99.
3. Roitt IM, Brostoff J, Male DK. Immunology, 5th edn, Churchill Livingston: London, 1998.
4. Sanfilippo F, Amos DB. An interpretation of the major histocompatibility complex. In: Rose NR, Friedman H, Fahey JL (eds). Manual of Clinical Laboratory Immunology, 3rd edn. ASM Press: Washington, 1986.
5. Moscoso J, Serrano-Vela JI, Pacheco R et al. HLA-G, -E and -F: allelism, function and evolution. Transpl Immunol 2006;17:61-4.
6. Janeway CA, Travers P. Antigen recognition by T lymphocytes. Immuno-biology, 3rd edn, Garland Publishing: New York and London, 1997, pp. 41-6.
7. McCluskey J, Peh CA. The human leukocyte antigens and clinical medicine: an overview. Rev Immunogenet 1999;1:3-20.
8. Sullivan KA, Amos DB. The HLA system and its detection. In: Rose NR, Friedmil OH, Fahey JL (eds). Manual of Clinical Laboratory Immunology, 3rd edn, ASM Press: Washington, 1986.
9. Jin P, Wang E. Polymorphism in clinical immunology. From HLA typing to immunogenetic profling. J Transl Med 2003;1:1-11.
10. Piancatelli D. Human leukocyte antigen-A, -B, and -Cw polymorphism in a Berber population from North Morocco using sequence-based typing. Tissue Antigens 2004;26:78-87.
11. Marsh SG, Albert ED, Bodmer WF et al. Nomenclature for factors of the HLA system, 2004. Tissue Antigens 2005;65:301-69.
12. Schreuder GM, Hurley CK, Marsh SGE et al. The HLA dictionary 2004: a summary of HLA-A, -B, -C, -DRB1/3/5 and -DQB1 alleles and their association with serologically denned HLA-A, -B, -C, -DR and -DQ antigens. Tissue Antigens 2005;65:1-55.
13. Robinson J, Waller MJ, Parham P et al. IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acid Res 2003;31:311-4.
14. Ferrer A, Fernández ME, Nazabal M. Overview on HLA and DNA typing methods. Biotecnología Aplicada 2005;22:91-101.
15. Shankarkumar U. The human leukocyte antigen (HLA) system. Int J Hum Genet 2004;4:91-103.
16. Marsh SG, Albert ED, Bodmer WF et al. HLA nomenclature report. Tissue Antigens 2002;60:407-64.
17. Williams TM. Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. J Mol Diag 2001;3:98-104.
18. Thorsby E. HLA associated diseases. Hum Immunol 1997;53:1-11.
19. Lechler R, Warrens A (eds). HLA in Health and Disease. Academic Press Limited: London, 2000.
20. McDevitt HO. The HLA system and its relation to disease. Hosp Pract 1985;20:57.
21. Catassi C, Ratsch IM, Fabiani E et al. Coeliac disease in the year 2000: exploring the iceberg. Lancet 1994;343:200-3.
22. Walker-Smith JA, Guandalini S, Schmitz J et al. Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child 1990;65:909-11.
23. United European Gastroenterology. When is a coeliac a celiac? Report of a working group of the United European Gastroenterology Week in Amsterdam, 2001. Eur J Gastroenterol Hepatol 2001:13:1123-8.
24. Falchuck ZM, Rogentine GN, Strober W. Predominance of histocompatibil-ity antigen HLA-B8 in patients with gluten-sensitive enteropathy. J Clin Invest 1972;51:1602.
25. Stokes PL, Asquith P, Holmes GK et al. Histocompatibility antigens associated with adult coeliac disease. Lancet 1972;2:162-4.
26. De Marchi M, Borelli I, Olivetti E et al. Two HLA-DR alleles are associated with celiac disease. Tissue Antigens 1979;14:309-16.
27. Zubillaga P, Vidales MC, Zubillaga I et al. HLA-DQA1 and HLA-DQB1 genetic markers and clinical presentation in coeliac disease. J Pediatr Gastroenterol Nutr 2002;34:548-54.
28. Congia M, Cucca F, Frau F et al. A gene dosage effect of the DQAl*0501/DQBl*0201 allelic combination influences the clinical heterogeneity of coeliac disease. Hum Immunol 1994;40:138-42.
29. Sollid LM, Markussen G, Ek J et al. Evidence for a primary association of coeliac disease to a particular HLA-DQ α β heterodimer. J Exp Med 1989;169:345-50.
30. Tosi R, Vismara D, Tanigaki N et al. Evidence that celiac disease is primarily associated with a DQ locus allelic specificity. Clin Immunol Immunopathol 1983;28:395-404.
31. van Rood JJ, van Leeuwen A, Keuning JJ et al. Evidence for two series of B-cell antigens in man and their comparison with HLA-D. Scand J Immunol 1977;6:373-84.
32. Duquesnoy RJ, Marrari M, Annen K. Identification of an HLA-DR-associated system of B-cell alloantigens. Transplant Proc 1979;11:1757-60.
33. Tighe MR, Hall MA, Barbado M et al. HLA class II alleles associated with coeliac disease susceptibility in a southern European population. Tissue Antigens 1992;40:90-7.
34. Louka AS, Nilsson S, Olson JM et al. An autosomal screen for genes that predispose to celiac disease in the western counties of Ireland. Nat Genet 1996;14:329-33.
35. van de Wai Y, Kooy YM, Drijfhout JW et al. Unique peptide binding characteristics of the disease-associated DQ(alphal*0501, betal*0201) vs the non-disease-associated DQ(alphal*0201, betal*0202) molecule. Immunogenetics 1997;46:484-92.
36. Sollid LM, Thorsby E. HLA susceptibility genes in coeliac disease: genetic mapping and role in pathogenesis. Gastroenterology 1993;105: 910-22.
37. Louka AS, Sollid LM. HLA in coeliac disease: unravelling the complex genetics of a complex disorder. Tissue Antigens 2003;61:105-17.
38. Mazzarella G, Maglio M, Paparo F et al. An immunodominant DQ8 restricted gliadin peptide activates small intestinal immune response in in vitro cultured mucosa from HLA-DQ8 positive but not HLA-DQ8 negative coeliac patients. Gut 2003;52:57-62.
39. Spurkland A, Sollid LM, Polanco I et al. HLA-DR and -DQ genotypes of celiac disease patients serologically typed to be non-DR3 or non-DR5/7. Hum Immunol 1992;35:188-92.
40. Polvi A, Arranz E, Fernandez-Arquero M et al. HLA-DQ2-negative celiac disease in Finland and Spain. Hum Immunol 1998;59:169-75.
41. King AL, Ciclitira PJ. Celiac disease: strongly eritable, oligogenic, but genetically complex. Mol Genet Metab 2000;71:70-5.
42. Sollid LM. Molecular basis of celiac disease. Annu Rev Immunol 2000;18:53-81.
43. Karell K, Louka AS, Mooedie SJ et al. HLA types in coeliac disease patients not carrying the DQA1*O5-DQB1*O2 (DQ2) heterodimer: results from the European Genetics Cluster on Coeliac Disease. Hum Immunol 2003;34:548-54.
44. Vader W, Stepniak D, Kooy Y et al. The HLA-DQ2 gene dose effect in coeliac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci USA 2003;100: 12390-5.
45. Margaritte-Jeannin P, Babron MC, Bourgey M et al. HLA-DQ relatives risk for coeliac disease in European population: a study of the European Genetic cluster on coeliac disease. Tissue Antigens 2004;63: 562-7.
46. van Belzen MJ, Koeleman BP, Crusius JB et al. Defining the contribution of the HLA region to cis DQ2-positive coeliac disease patients. Genes Immun 2004;5:215-20.
47. Al-toma A, Goerres M, Meijer JWR et al. Human leukocyte antigen DQ2 homozigosity and the development of refractory coeliac disease and enteropathy-associated T-cell lymphoma. Clin Gastroenterol Hepatol 2006;4:315-9.
48. Ploski R, Ek J, Thorsby E et al. On the HLA-DQ (α*0501, β*0201) associated susceptibility in coeliac disease: a possible gene dosage effect of DQBl*0201. Tissue Antigens 1993;41:173-7.
49. Karinen H, Karkkainen P, Pihlajamaki J et al. Gene dose effect of the DQBl*0201 allele contributes to severity of coeliac disease. Scand J Gastroenterol 2006;41:191-9.
50. Jores RD, Frau F, Cucca F et al. HLA-DQBl*0201 homozygosis predisposes to severe intestinal damage in celiac disease. Scand J Gastroenterol 2007;42:48-53.
51. Deleeuw R, Zettl A, Klinker E et al. Whole-genome analysis and HLA geno typing of enteropathy-type T-Cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 2007;132:1902-ll.
52. Louka AS, Nilsson S, Olsson M et al. HLA in coeliac disease families: a novel test of risk modification by the 'other' haplotype when at least one DQA1*O5-DQB1*O2 haplotype is carried. Tissue Antigens 2002;60: 147-54.
53. Greco L, Percopo S, Clot F et al. Lack of correlation between genotype and phenotype in celiac disease. J Pediatr Gastroenterol Nutr 1998;26:286-90.
54. Greco L, Romino R, Coto I et al. The first large population based twin study of coeliac disease. Gut 2002;50:624-8.
55. Bolognesi E, Karell K, Percopo S et al. Additional factor in some HLA DR3/DQ2 haplotypes confers a fourfold increased genetic risk of celiac disease. Tissue Antigens 2003;61:308-16.
56. Louka A, Moodie S, Karell K et al. A collaborative European search for non-DQAl*05-DQBl*02 celiac disease loci on HLA-DR3 haplotypes: analysis of transmission from homozygous parents. Hum Immunol 2003;64:350-8.
57. Mustalahti K, Holopainen P, Karel K et al. Genetic dissection between silent and clinically diagnosed symptomatic forms of coeliac disease in multiplex families. Dig Liv Dis 2002;34:842-5.
58. Vogelsang MD, Panzer S, Mayr WR. Distribution of HLA class I alleles differs in celiac disease patients according to age of onset. Dig Dis Sci 2003;48:611-4.
59. Congia M, Frau F, Lampis R et al. A high frequency of the A30, B18, DR3, DRw52, DQw2 extended haplotype in Sardinian celiac disease patients: further evidence that disease susceptibility is conferred by DQ Al*0501, Bl*0201. Tissue Antigens 1992;39:78-83.
60. Kaur G, Sarkar N, Bhatnagar S et al. Pediatric celiac disease in India is associated with multiple DR3-DQ2 haplotypes. Hum Immunol 2002;63:677-82.
61. Ruiz MY, Olivares JL. Three-loci HLA haplotypes in Spanish celiac children and healthy subjects: estimation of linkage disequilibrium and haplotype frequencies. Am J Gastroenterol 2001;96:1455-9.
62. Schuppan D, Hahn EG. IgA anti-tissue transglutaminase: setting the stage for coeliac disease screening. Eur J Gastroenterol Hepatol 2001;13:635-7.
63. Tommasini A, Not T, Kiren V et al. Mass screening for coeliac disease using antihuman transglutaminase antibody assay. Arch Dis Child 2004;89:512-5.
64. Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006;131:1981-2002.
65. Mearin ML, Ivarsson I, Dickey W Coeliac disease: is it time for mass screening? Best Pract Res Clin Gastroenterol 2005;19:441-52.
66. Green PH, Jabri B. Coeliac disease. Lancet 2003;362:383-91.
67. Akobeng AK. Understanding diagnostic tests 2: likelihood ratios, pre- and post-test probabilities and their use in clinical practice. Acta Paediatr 2007;96:487-91.
68. Maki M, Holm K, Lipsanen V et al. Serological markers and HLA genes among healthy first-degree relatives of patients with coeliac disease. Lancet 1991;338:1350-3.
69. Karinen H, Karkkainen P, Pihlajamaki J et al. HLA genotyping is useful in the evaluation of the risk for coeliac disease in the lst-degree relatives of patients with coeliac disease. Scand J Gastroenterol 2006;41:1299-304.
70. Hill ID. What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificiy vary in different populations? Gastroenterology 2005;128:S25-32.
71. Bonamico M, Ferri M, Mariani P et al. Serologic and genetic markers of celiac disease: a sequential study in the screening of first degree relatives. J Pediatr Gastroenterol Nutr 2006;42:150-4.
72. Bourgey M, Calcagno G, Tinto N et al. HLA related genetic risk for coeliac disease. Gut 2007;56:1054-9.
73. Cronin CC, Shanahan F. Insulin-dependent diabetes mellitus and celiac disease. Lancet 1997;349:1096-7.
74. Hansen D, Bennedbaeck F, Hansen L et al. High prevalence of celiac disease in Danish children with type 1 diabetes mellitus. Acta Paediatr 2001;90:1238-43.
75. Shanahan F, McKenna R, McCarthy CF et al. Celiac disease and diabetes mellitus: a study of 24 patients with HLA-typing. Q J Med 1992;51:329-35.
76. Thorsby E, Undlien D. The HLA associated predisposition to type 1 diabetes and other autoimmune diseases. J Pediatr Endocrinol Metabol 1996;9:75-88.
77. Todd JA, Bell JI, McDevitt HO. HLA DQβ-gene contributes to susceptibility and resistance to insulin-dependent diabetic individuals. Nature 1987;329:599-604.
78. Tosi G, Mantero G, Magalini AR et al. HLA-DQB1 typing of north-east Italian IDDM patients using amplified DNA, oligonucleotide probes and a rapid DNA-enzyme immunoassay (DEIA). Mol Immunol 1993;30:69-76.
79. Lampasona V, Ferrari M, Bonifacio E et al. HLA-DQ screening for risk assessment of insulin dependent diabetes in northern Italy. Acta Diabetol 1995;32:137-42.
80. Saukkonen T, Savilahti E, Reijonen H et al. Coeliac disease: frequent occurrence after clinical onset of insulin-dependent diabetes mellitus. Childhood Diabetes in Finland Study Group. Diabet Med 2006;13:464-70.
81. Contreas G, Valletta E, Ulmi D et al. Screening of coeliac disease in north Italian children with type 1 diabetes: limited usefulness of HLA-DQ typing. Acta Paediatr 2004;93:628-32.
82. Doolan A, Donaghut K, Fairchild J et al. Use of HLA typing in diagnosing celiac disease in patients with type 1 diabetes. Diabet Care 2005;28:806-9.
83. Sumnik Z, Cinek O, Bratanic N et al. Risk of celiac disease in children with type 1 diabetes is modified by positivity for HLA-DQB1*O2- DQA1*O5 and TNFα308A. Diabet Care 2006;29:858-63.
84. Holmes GKT. Celiac disease and type 1 diabetes mellitus - the case for screening. Diabetes 2001;18:169-77.
85. Kaukinen KPJ, Maki M, Collin P. HLA-DQ typing in the diagnosis of celiac disease. Am J Gastroenterol 2002;97:695-9.
86. Freemark M, Levitsky LL. Screening for celiac disease in children with type 1 diabetes: two views of the controversy. Diabet Care 2003;26:1932-9.
87. George EK, Mearin ML, Bouquet J et al. High frequency of celiac disease in Down syndrome. J Pediatr 1996;128:555-7.
88. Csizmadia CGDS, Mearin ML, Oren A et al. Accuracy and cost-effectiveness of a new strategy to screen for celiac disease in children with Down syndrome. J Pediatr 2000;137:756-61.
89. Kapitany NY, To'th L, Tumpek J et al. Diagnostic significance of HLA-DQ typing in patients with previous coeliac disease diagnosis based on histology alone. Aliment Pharmacol Ther 2006;24:1395-402.
90. Castano L, Blarduni E, Ortiz L et al. Prospective population screening for celiac disease: high prevalence in the first 3 years of life. J Pediatr Gastroenterol Nutr 2004;39:80-4.
91. Hadithi M, von Blomberg M, Crusius BA et al. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Ann Intern Med 2007;147:294-302.
92. Dorn SD, Matchar DB. Cost-effectiveness analysis of strategies for diagnosing celiac disease. Dig Dis Sci 2008;53:680-8.
93. Viljamaa M, Collin P, Huhtala H et al. Is celiac disease screening in risk groups justified? A fourteen-year follow up with special focus on compliance and quality of life. Aliment Pharmacol Ther 2005;22:317-24.
94. Liu E, Rewers M, Eisenbarth GS. Genetic testing: who should do the testing and what is the role of genetic testing in the setting of celiac disease? Gastroenterology 2005;128:S33-7.
95. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57.
96. Mathew CG, Lewis CM. Genetics of inflammatory bowel disease: progress and prospects. Hum Mol Genet 2004;13:R161-8.
97. Hampe J, Shaw SH, Saiz R et al. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet 1999;65:1647-55.
98. Gaya DR, Russell RK, Nimmo ER et al. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 2006;367:1271-84.
99. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3.
100. Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007;39:207-ll.
101. Rioux JD, Silverberg MS, Daly MJ et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000;66:1863-70.
102. Yang H, Plevy SE, Taylor KD et al. Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses. Gut 1999;44:519-26.
103. Bouma G, Crusius JB, Garda-Gonzalez MA et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 1999;115:294-300.
104. Stokkers PC, Reitsma PH, Tytgat GN et al. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 1999;45:395-401.
105. Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: the role of the HLA complex. World J Gastroenterol 2006;12:3628-35.
106. van Heel DA, Fisher SA, Kirby A et al. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet 2004;13:763-70.
107. Yap LM, Ahmad T, Jewell DP. The contribution of HLA genes to IBD susceptibility and phenotype. Best Pract Res Clin Gastroenterol 2004;18:577-96.
108. Danzé PM, Colombel JF, Jacquot S et al. Association of HLA class II genes with susceptibiliy to Crohn's disease. Gut 1996;39:69-72.
109. Reinshagen M, Loeliger C, Kuehnl P et al. HLA class II gene frequencies in Crohn's disease: a population based analysis in Germany. Gut 1996;38: 538-42.
110. Ahmad T, Armuzzi A, Bunce M et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002;122: 854-66.
111. Newman B, Silverberg MS, Gu X et al. CARD 15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's disease. Am J Gastroenterol 2004;99:306-15.
112. Fernandez L, Mendoza JL, Martinez A et al. IBD1 and IBD3 determine location of Crohn's disease in the Spanish population. Inflamm Bowel Dis 2004;10:715-22.
113. Satsangi J, Welsh KI, Bunce M et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996;347:1212-7.
114. Trachtenberg EA, Yang H, Hayes E et al. HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish Caucasian populations. Hum Immunol 2000;61:326-33.
115. Toyoda H, Wang SJ, Yang HY et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993;104:741-8.
116. Silverberg MS, Mirea L, Bull SB et al. A population-and family-based study of Canadian families reveals association of HLA DRBl*0103 with colonic involvement in inflammatory bowel disease. Inflamm Bowel Dis 2003;9:1-9.
117. de la Concha EG, Fernandez-Arquero M, Martinez A et al. Aminoacid polymorphism at residue 71 in HLA-DR beta chain plays a critical role in susceptibility to ulcerative colitis. Dig Dis Sci 1999;44:2324-9.
118. Yamamoto-Furusho JK, Uscanga LF, Vargas-Alarcon G et al. Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. Hum Immunol 2003;64:119-23.
119. Roussomoustakaki M, Satsangi J, Welsh K et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997;112:1845-53.
120. de La Concha EG, Fernandez-Arquero M, Santa-Cruz S et al. Positive and negative associations of distinct HLA-DR2 subtypes with ulcerative colitis (UC). Clin Exp Immunol 1997;108:392-5.
121. Gomez Garcia M, Oliver J, Marquez A et al. Strong protective effect of DR3 against ulcerative colitis in the Spanish population. Am J Gastroenterol 2007;102:1-5.
122. Purrmann J, Bertrams J, Knapp M et al. Gene and haplotype frequencies of HLA antigens in 269 patients with Crohn's disease. Scand J Gastroenterol 1990;25:981-5.
123. Matake H, Okabe N, Naito S et al. An HLA study on 149 Japanese patients with Crohn's disease. Gastroenterol Jpn 1992;27:496-501.
124. Nakajima A, Matsuhashi N, Kodama T et al. HLA-linked susceptibility and resistance genes in Crohn's disease. Gastroenterology 1995;109:1462-7.
125. Yoshitake S, Kimura A, Okada M et al. HLA class II alleles in Japanese patients with inflammatory bowel disease. Tissue Antigens 1999;53:350-8.
126. Fujita K, Naito S, Okabe N et al. Immunological studies in Crohn's disease. I. Association with HLA systems in the Japanese. J Clin Lab Immunol 1984;14:99-102.
127. Sugimura K, Asakura H, Mizuki N et al. Analysis of genes within the HLA region affecting susceptibility to ulcerative colitis. Hum Immunol 1993;36:112-8.
128. Kobayashi K, Atoh M, Yagita A et al. Crohn's disease in the Japanese is associated with the HLA-DRw53. Exp Clin Immunogenet 1990;7:101-8.
129. Asakura H, Tsuchiya M, Aiso S et al. Association of the human lymphocyte-DR2 antigen with Japanese ulcerative colitis. Gastroenterology 1982;82:413-8.
130. Leidenius MH, Koskimies SA, Kellokumpu IH et al. HLA antigens in ulcerative colitis and primary sclerosing cholangitis. APMIS 1995;103: 519-24.
131. Futami S, Aoyama N, Honsako Y et al. HLA-DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression. Dig Dis Sci 1995;40:814-8.
132. Myung SJ, Yang SK, Jung HY et al. HLA-DRB1*15O2 confers susceptibility to ulcerative colitis, but is negatively associated with its intractability: a Korean study. Int J Colorectal Dis 2002;17:233-7.
133. Cariappa A, Sands B, Fordone D et al. Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease. Gut 1998;43:210-5.
134. Biemond I, Burnham WR, D'Amaro J et al. HLA-A and -B antigens in inflammatory bowel disease. Gut 1986;27:934-41.
135. Kinouchi Y, Matsumoto K, Negoro K et al. HLA-B genotype in Japanese patients with Crohn's disease. Dis Colon Rectum 2003;46:S10-4.
136. Seki SS, Sugimura K, Ota M et al. Stratification analysis of MICA triplet repeat polymorphisms and HLA antigens associated with ulcerative colitis in Japanese. Tissue Antigens 2001;58:71-6.
137. Ahmad T, Armuzzi A, Neville M et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens 2003;62:527-35.
138. Danese S, Semeraro S, Papa A et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11:7227-36.
139. Orchard TR, Thiyagaraja S, Welsh KI et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000;118:274-8.
140. Orchard TR, Chua CN, Ahmad T et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002;123:714-8.
141. Turkcapar N, Toruner M, Soykan I et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int 2006;26:663-8.
142. De Vos M. Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther 2004;20 (Suppl 4): 36-42.
143. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-97.
144. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001;96:1224-31.
145. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938.
146. Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol 2006;22:234-40.
147. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000; 174: 250-9.
148. Czaja AJ, Manns MR The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol 1995;90:1206-11.
149. Czaja AJ. Autoimmune hepatitis - approach to diagnosis. MedGenMed 2006;82:55.
150. Donaldson PT, Doherty DG, Hayllar KM et al. Susceptibility to autoimmune chronic active hepatitis: human leucocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991:13:701-6.
151. Czaja AJ, Strettell MDJ, Thomson LJ et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997;25:317-23.
152. Djilali I, Renousi R, Caillat-Zucman S et al. Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J Hepatol 2004;40:904-9.
153. Czaja AJ, Carpenter HA, Santrach PJ et al. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993;105:1502-7.
154. Czaja AJ, Kruger M, Santrach PJ et al. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 1997;92: 2197-200.
155. Doherty DG, Donaldson PT, Underhill JA et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994;19:609-15.
156. Strettel MDJ, Donaldson PT, Thomson LJ et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997;112:2028-35.
157. Seki T, Kiyosawa K, Inoko H et al. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 1990;12: 1300-4.
158. Seki T, Ota M, Furuta S et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992:103:1041-7.
159. Yoshizawa K, Ota M, Katsuyama Y et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol 2005;42:578-84.
160. Muratori P, Czaja AJ, Muratori L et al. Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol 2005;11:1862-6.
161. Shankarkumar U, Amarapurkar DN, Kankonkar S. Human leukocyte antigen allele associations in type-1 autoimmune hepatitis patients from western India. J Gastroenterol Hepatol 2005:20:193-7.
162. Qiu D-K, Ma X. Relationship between human leukocyte antigen-DRBl and autoimmune hepatitis type I in Chinese patients. J Gastroenterol Hepatol 2003:18:63-7.
163. Bittencourt PL, Goldberg AC, Cancado ELR et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999:94:1906-13.
164. Marcos Y, Fainboim HA, Capucchio M et al. Two-locus involvement in the association of human leukocyte antigen with the extrahepatic manifestations of autoimmune chronic active hepatitis. Hepatology 1994:19:1371-4.
165. Fainboim L, Marcos Y, Pando M et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA DR6 (DRB1*13O1) haplotype. Hum Immunol 1994;41:146-50.
166. Pando M, Larriba J, Fernandez GC et al. Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30:1374-80.
167. Vazquez-Garcia MN, Alaez C, Olivo A et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998;28:985-90.
168. Fortes Mdel R Machado IV, Gil G et al. Genetic contribution of major histocompatibility complex class II region to typel autoimmune hepatitis susceptibility in Venezuela. Liver Int 2007;27:1409-16.
169. Czaja AJ, Carpenter HA, Moore SM. HLA DRB1*13 as a risk factor for type 1 autoimmune hepatitis in North American patients. Dig Dis Sci 2008:53:522-8.
170. D'Souza R, Sinnott P, Glynn MJ et al. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 2005;25:325-30.
171. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97:413-9.
172. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97:2051-7.
173. Czaja AJ, Cassani F, Cataleta M et al. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci 1997;42:1688-96.
174. Granito A, Muratori L, Pappas G et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther 2005;21:1273-7.
175. Czaja A, Cassani F, Cataleta M et al. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996;24:1068-73.
176. Czaja AJ, Rakela J, Hay JE et al. Clinical and prognostic implications of human leukocyte antigen B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1990;98:1587-93.
177. Sanchez-Urdazpal L, Czaja AJ, van Hoek B et al. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992;15:215-21.
178. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007;46:1138-45.
179. Gonzalez-Koch A, Czaja AJ, Carpenter HA et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;4:302-10.
180. Montano-Loza AJ, Carpenter HA, Czaja AJ. Clinical significance of HLA DRB1*O3-DRB1*O4 in type 1 autoimmune hepatitis. Liver Int 2006;26:1201-8.
181. Manns MR Kruger M. Immunogenetics of chronic liver diseases. Gastroenterology 1994;106:1676-97.
182. Homberg JC, Abuaf N, Bernard O et al. Chronic active hepatitis associated with anti-liver kidney microsome type 1: a second type of "autoimmune" hepatitis. Hepatology 1987;7:1333-9.
183. Gregorio GV, Portman B, Reid F et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541-7.
184. Lenzi M, Mantovani W, Cataleta M et al. HLA typing in autoimmune hepatitis (AI-CAH) type 2. J Hepatol 1992;16:59 (abstract).
185. Manns M, Jensch M, Mergener K et al. HLA class I-III in autoimmune hepatitis type 2 and its association with hepatitis C virus infection. J Hepatol 1991;16 (Suppl 1): 16 (abstract).
186. Jurado A, Cardaba B, Jara P et al. Autoimmune hepatitis type 2 and hepatitis C virus infection: study of HLA antigens. J Hepatol 1997;26:983-91.
187. Manns M, Scheucher S, Jentzsch M et al. Genetics in autoimmune hepatitis type 2. Hepatology 1991;14:60 (abstract).
188. Lenzi M, Mantovani W, Donaldson PT et al. Genetic background in type 2 autoimmune hepatitis. Hepatology 1997;26:443A.
189. Djilali-Saiah I, Faknfakh A, Louafi H et al. HLA Class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol 2006;45:844-50.
190. Manabe K, Donaldson PT, Underhill JA et al. Human Leukocyte antigen Al-B8-DR3-DQ2-DPBl*0401 extended haplotype in autoimmune hepatitis. Hepatology 1993;18:1334-7.
191. Strettell MDJ, Thomson LJ, Donaldson PT et al. HLA-C genes and susceptibility to type 1 autoimmune hepatitis. Hepatology 1997;26:1023-6.
192. Teufel A, Wörns M, Weinmann A et al. Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients. World J Gastroenterol 2006;12:5513-6.
193. LaRusso NF, Shneider BL, Black D et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006;44:746-64.
194. Schrumpf E, Boberg KM. Epidemiology of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:553-62.
195. Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis 2005;11:62-72.
196. Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 2004;53:599-608.
197. Donaldson PT, Norris S. Immunogenetics in PSC. Best Pract Res Clin Gastroenterol 2001;15:611-27.
198. Karlsen TH, Schrumpf E, Boberg KM. Genetic epidemiology of primary sclerosing cholangitis. World J Gastroenterol 2007;13:5421-31.
199. Bergquist A, Lindberg G, Saarinen S et al. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005;42:252-6.
200. Donaldson PT, Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 2002;35:555-64.
201. Norris S, Kondeatis E, Collins R et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology 2001;120:1475-82.
202. Moloney MM, Thomson LJ, Strettell MJ et al. Human leukocyte antigen-C genes and susceptibility to primary sclerosing cholangitis. Hepatology 1998;28:660-2.
203. Schrumpf E, Fausa O, Fùrre E et al. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol 1982:17:187-91.
204. Shepherd HA, Selby WS, Chapman RWG et al. Ulcerative colitis and persistent liver dysfunction. Q J Med 1983;52:503-13.
205. Chapman RW, Varghese Z, Gaul R et al. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983;24:38-41.
206. Donaldson PT, Farrant JM, Wilkinson ML et al. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991;13:129-33.
207. Prochazka II, Terasaki PI, Park MS et al. Association of primary sclerosing cholangitis with HLA DRw52a. N Engl J Med 1990;322:1842-4.
208. Park MS, Terasaki PI. Inability to attribute susceptibility to primary sclerosing cholangitis to specific amino acid positions of the HLA-DRw52a allele. N Engl J Med 1991;325:1252.
209. Farrant JM, Doherty DG, Donaldson PT et al. Amino acid substitutions at position 38 of the DRP polypeptide confer susceptibility and protection from primary sclerosing cholangitis. Hepatology 1992;16:390-5.
210. Underhill JA, Donaldson PT, Doherty DG et al. HLA DPB polymorphism in primary sclerosing cholangitis and primary biliary cirrhosis. Hepatology 1995;21:959-62.
211. Mehal WZ, Lo Y-MD, Wordsworth BP et al. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1994;106:160-7.
212. Olerup O, Olsson R, Hultcrantz R et al. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1995;108:870-8.
213. Spurkland A, Saarinen S, Boberg KM et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999;53:459-69.
214. Noguchi K, Kobayashi M, Yagihashi A et al. HLA antigens in primary sclerosing cholangitis. Transplant Proc 1992;24:2775-6.
215. Wiencke K, Karlsen TH, Boberg KM et al. Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes. Tissue Antigens 2007;69:161-9.
216. Neri TM, Cavestro GM, Seghini P et al. Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population. Dig Liver Dis 2003;35:571-6.
217. Gow PJ, Fleming KA, Chapman RW. Primary sclerosing cholangitis associated with rheumatoid arthritis and HLA DR4: is the association a marker of patients with progressive liver disease? J Hepatol 2001;34:631-5.
218. Boberg KM, Spurkland A, Rocca G et al. The HLA-DR3, DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol 2001;36:886-90.
219. Donaldson PT, Norris S, Underhill JA et al. HLA associations in primary sclerosing cholangitis are present only in those patients with concurrent inflammatory bowel disease. Hepatology 1998;28 (Abstract no. 918): 392A.
220. Bittencourt PL, Palacios SA, Cançado ELR et al. Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB1*13 but not with tumour necrosis factor a -308 promoter polymorphism. Gut 2002;51:609-16.
221. Karlsen TH, Boberg KM, Vatn M et al. Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. Genes Immun 2007;8:275-8.
222. Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet 2003;362: 53-61.
223. Gershwin ME, Selmi C, Worman HJ et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005;42:1194-202.
224. Selmi C, Mayo MJ, Bach N et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004;127:485-92.
225. Tsuji K, Watanabe Y, Van De Water J et al. Familial primary biliary cirrhosis in Hiroshima. J Autoimmun 1999;13:171-8.
226. Invernizzi P, Selmi C, Mackay IR et al. From bases to basis: linking genetics to causation in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2005;3:401-10.
227. Selmi C, Invernizzi P, Zuin M et al. Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis 2005;25:265-80.
228. Galbraith RM, Eddleston AL, Smith MGM et al. Histocompatibility antigens in active chronic hepatitis and primary biliary cirrhosis. Br Med J 1974;2:604-5.
229. Erdlla G, Parés A, Arriaga F et al. Primary biliary cirrhosis associated with DLA-DRw3. Tissue Antigens 1979;14:449-52.
230. Miyamori H, Kato Y, Kobayashi K et al. HLA antigens in Japanese patients with primary biliary cirrhosis and autoimmune hepatitis. Digestion 1983;26:213-7.
231. Onishi S, Sakamaki T, Maeda T et al. DNA typing of HLA class II genes: DRBl*0803 increases the susceptibility of Japanese to primary biliary cirrhosis. J Hepatol 1994;21:1053-60.
232. Bassendine MF, Dewar PJ, James OF. HLA-DR antigens in primary biliary cirrhosis: lack of association. Gut 1985;26:625-8.
233. Briggs DC, Donaldson PT, Hayes P et al. A major histocompatibility complex class III allotype (C4B 2) associated with primary biliary cirrhosis (PBC). Tissue Antigens 1987;29:141-5.
234. Manns MP, Bremm A, Schneider PM et al. HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology 1991;101:1367-73.
235. Morling N, Dalhoff K, Fugger L et al. DNA polymorphism of HLA class II genes in primary biliary cirrhosis. Immunogenetics 1992;35:112-6.
236. Invernizzi P, Battezzati PM, Crosignani A et al. Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. J Hepatol 2003;38:401-6.
237. Leuschner M, Dietrich CF, You T et al. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 2000;46:121-6.
238. Gores GJ, Moore SB, Fisher LD et al. Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens. Hepatology 1987;7:889-92.
239. Begovich AB, Klitz W, Moonsamy PV et al. Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis. Tissue Antigens 1994;43:71-7.
240. Wassmuth R, Depner F, Danielsson A et al. HLA class II markers and clinical heterogeneity in Swedish patients with primary biliary cirrhosis. Tissue Antigens 2002;59:381-7.
241. Underhill J, Donaldson P, Bray G et al. Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8 DQBl*O402 haplotype. Hepatology 1992;16:1404-8.
242. Gregory W, Mehal W, Dunn AN et al. Primary biliary cirrhosis: contribution of HLA class II allele DR8. Q J Med 1993;86:393-9.
243. Zhang L, Weetman AR Bassendine M et al. Major histocompatibility complex class-II alleles in primary biliary cirrhosis. Scand J Immunol 1994;39:104-6.
244. Mullarkey ME, Stevens AM, McDonnell WM et al. Human leukocyte antigen class II alleles in Caucasian women with primary biliary cirrhosis. Tissue Antigens 2005;65:199-205.
245. Jones DEJ, Donaldson PT. Genetic factors in the pathogenesis of primary biliary cirrhosis. Clin Liver Dis 2003;7:841-64.
246. Bittencourt PL, Palacios SA, Farias AQ et al. Analysis of major histocompatibility complex and CTLA-4 alleles in Brazilian patients with primary biliary cirrhosis. J Gastroenterol Hepatol 2003;18:1061-6.
247. Donaldson PT, Baragiotta A, Heneghan MA et al. HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology 2006;44:667-74.
248. Donaldson R Agarwal K, Craggs A et al. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut 2001;48:397-402.
249. Stone J, Wade JA, Cauch-Dudek K et al. Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol 2002;36:8-13.
250. Mella JG, Roschmann E, Maier KP et al. Association of PBC with the allele HLA-DPBl*0301 in a German population. Hepatology 1995;21:398-402.
251. Seki T, Kiyosawa K, Ota M et al. Association of primary biliary cirrhosis with human leukocyte antigen DPBl*0501 in Japanese patients. Hepatology 1993;18:73-8.
252. Oguri H, Oba S, Ogina H et al. Susceptibility to primary biliary cirrhosis is associated with human leukocyte antigen DRBl*0803 in Japanese patients. Int Hepatol Commun 1994;2:263-70.
253. Maeda T, Onoshi S, Saibara T et al. HLA DR8 and primary biliary cirrhosis. Gastroenterology 1992;103:1118-9.
254. Mukai T, Kimura A, Ishibashi H et al. Association of HLA-DRBl*0803 and 1602 with susceptibility to primary biliary cirrhosis. Int Hepatol Commun 1995;3:207-12.
255. Liu HY, Deng AM, Zhou Y et al. Analysis of HLA alleles polymorphism in Chinese patients with primary biliary cirrhosis. Hepatobiliary Pancreat Dis Int 2006;5:129-32.
256. Invernizzi R Selmi C, Poli F et al. HLA DRB1 polymorphisms in 676 Italian patients with primary biliary cirrhosis and 2028 matched healthy controls. A nation-wide population based case-control study. Hepatology 2005;42:462A.
257. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360-5.
258. Chazouilleres O, Wendum D, Serfaty L et al. Primary biliary cirrhosisautoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296-301.
259. Zetterquist H, Broome U, Einarsson K et al. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis. Gut 1992;33:942-6.
260. Lohse AW, zum Büschenfelde KH, Franz B et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29:1078-84.
261. Czaja AJ, Santrach PJ, Breanndan Moore S. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 2001;46:140-7.
262. Castillo Palma MJ, Sanchez Roman J, Ocana Medina C et al. Serologic and molecular HLA typing in patients from Andalucia with Behçefs disease. Genetic and clinical correlations. Med Clin (Barc) 1996;106: 121-5.
263. Fine KD, Do K, Schulte K et al. High prevalence of coeliac sprue-like HLA-DQ genes and enteropathy in patients with the microscopic colitis syndrome. Am J Gastroenterol 2000;95:1974-82.
264. Fernandez-Banares F, Salas A, Esteve M et al. Collagenous and lymphocytic colitis: evaluation of clinical and histological features, response to treatment, and long-term follow up. Am J Gastroenterol 2003;98:340-7.
265. Gillet HR, Freeman HJ. Prevalence of coeliac disease in collagenous and lymphocytic colitis. Can J Gastroenterol 2000;14:919-21.
266. Matteoni CA, Goldblum JR, Wang N et al. Coeliac disease is highly prevalent in lymphocytic colitis. J Clin Gastroenterol 2001;32: 225-7.
267. Pickartz T, Mayerle J, Lerch MM. Autoimmune pancreatitis. Nat Clin Pract Gastroenterol Hepatol 2007;4:314-23.
268. Kawa S, Ota M, Yoshizawa K et al. HLA-DRBl*0405- DQBl*0401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology 2002;122:1264-9.
269. Ota M, Katsuyama Y, Hamano H et al. Two critical genes (HLA-DRB1 and ABCF1) in the HLA region are associated with the susceptibility to autoimmune pancreatitis. Immunogenetics 2007;59:45-52.
270. Zmijewski CM. HLA and disease. Crit Rev Clin Lab Sci 1984;20: 285-373.